Publication
Baseline serum carcinoembryonic antigen (CEA) is an independent prognostic biomarker for metastatic castration-resistant prostate cancer (mCRPC) patients receiving 177Lu-PSMA therapy.
Emilio Francesco Giunta, Irene Marini, Ilaria Grassi, Silvia Nicolini, Flavia Foca, Monica Celli, Paola Caroli, Anna Sarnelli, Nicole Brighi, Giuseppe Schepisi, Manuela Monti, Ugo De Giorgi, Cristian Lolli, Maddalena Sansovini
- Source
- PubMed
- Retrieved
- Sep 13, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260913-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
PURPOSE: 177Lu-PSMA is currently approved for metastatic castration-resistant prostate cancer (mCRPC). However, only a subset of eligible patients derives a meaningful clinical benefit from treatment. To date, there is a lack of validated biomarkers that could help find the best candidates for this…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Candidate 1
- cancerMalignant Prostate Neoplasmdictionary0.60
Curated evidence
Evidence citing this paper (0)
Data not yet available